Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the new pill format of the ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Novo Nordisk anticipates oral weight-loss drugs will capture one-third or more of the GLP-1 market by 2030, driven by ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...